Short answer: Nimodipine and nicardipine are both dihydropyridine calcium channel blockers, but they’re used for different purposes and have different administration routes.
Key differences
- Primary use
- Nimodipine: Specifically to prevent cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH). Not a general blood-pressure drug.
- Nicardipine: General blood pressure control (including hypertensive emergencies) and sometimes used in perioperative settings; also available for chronic hypertension and angina.
- Route and formulation
- Nimodipine: Oral only. There is no approved IV form because IV nimodipine can cause deadly hypotension.
- Nicardipine: Both IV and oral forms. IV nicardipine is common in the hospital for acute BP control; oral for chronic HTN.
- Mechanism and selectivity
- Both block L-type calcium channels in smooth muscle.
- Nimodipine is more lipophilic and tends to dilate cerebral arteries, giving relatively more cerebral selectivity (hence its use in SAH to reduce vasospasm risk). It still can lower BP, but it’s chosen for the brain vascular effect.
- Nicardipine causes systemic vasodilation and is a potent antihypertensive; not specifically targeted to cerebral vessels.
- Typical dosing
- Nimodipine (SAH): Usually 60 mg orally every 4 hours for 21 days (start within a few days after SAH as guided by a clinician; take with or without food per labeling). Do not use IV.
- Nicardipine:
- IV: Start about 5 mg/hour; titrate by 2.5 mg/hour every 5–15 minutes to achieve BP goal; typical max around 15 mg/hour (adjust as needed and per protocol).
- Oral: Dosing varies for chronic HTN and other indications (often in the tens of milligrams per dose, given 1–2 or 3–4 times daily, adjusted to BP and tolerance).
- Common side effects
- Both: Hypotension, headache, dizziness, flushing, edema.
- Nimodipine may cause cerebral-related effects (headache, dizziness) and is avoided in IV form to prevent severe hypotension.
- Nicardipine may cause reflex tachycardia and significant systemic hypotension with IV use.
- Important interactions and cautions
- Both are metabolized by CYP3A4; strong inhibitors or inducers can raise or lower levels (eg, some macrolide antibiotics, azole antifungals, grapefruit juice with nimodipine).
Nimodipine should not be given IV, and its use is largely confined to SAH-related care under a clinician’s guidance.
Nicardipine IV is used in hospital settings to control BP; monitor closely for BP and heart rate.
Bottom line
- If you’re treating SAH to prevent vasospasm, nimodipine is the drug of choice (oral, not IV).
- If you need to rapidly lower blood pressure or manage BP in the hospital, nicardipine (often IV) is the go-to option.
- They’re both CCBs, but their indications, routes, and clinical roles are different.
If you share the exact condition or scenario (eg, SAH after aneurysm, hypertensive emergency, chronic HTN), I can tailor the comparison and dosing notes more precisely. Also, always follow the prescriber’s guidance and product labeling.